Skip to main content
Home
FULL MENU Close Menu
Home
Home

Bruce Jancin

News

Recent psoriasis pathophysiology insights carry treatment implications

Author:
Bruce Jancin
Publish date: March 4, 2021

“The primary problem in psoriasis is not so much the inflammatory activity, but the ability to turn off the activity.”

  • Read More

News

RA experts highlight key developments over the past year

Author:
Bruce Jancin
Publish date: March 3, 2021

Highlights include lymphoma risk reduction with biologics, low-dose corticosteroid risk, stratifying VTE risk, treat-to-target strategies and...

  • Read More

News

Rise of JAK inhibitors highlights axial spondyloarthritis year in review

Author:
Bruce Jancin
Publish date: February 25, 2021

Panelists at the 2021 Rheumatology Winter Clinical Symposium discussed the impact JAK inhibitors will have on the management of patients with...

  • Read More

News

Romosozumab may not increase cardiovascular risk after all

Author:
Bruce Jancin
Publish date: February 17, 2021

Could a cardioprotective effect of bisphosphonates in a pivotal clinical trial of romosozumab explain why the biologic was given a black-box...

  • Read More

News

Consider home subcutaneous immune globulin for refractory dermatomyositis

Author:
Bruce Jancin
Publish date: February 17, 2021

Patients prefer home subQ over IVIg, citing greater feeling of autonomy.

  • Read More

News

Molecular insights suggest novel therapies for hidradenitis suppurativa

Author:
Bruce Jancin
Publish date: February 10, 2021

Many key molecular pathways involved in HS pathogenesis can be targeted by commercially available agents having other indications.

  • Read More

News

Anybody for a nanobody? Novel psoriasis therapy impresses in phase 2b

Author:
Bruce Jancin
Publish date: February 10, 2021

Sonelokinab, which inhibits interleukin-17A/F, provided exceptionally rapid clinical improvement.

  • Read More

News

Neoadjuvant immunotherapy shows promise in stage III melanoma

Author:
Bruce Jancin
Publish date: February 10, 2021

There is both preclinical and clinical evidence that neoadjuvant therapy may offer a survival advantage over adjuvant therapy.

  • Read More

News

Delusional infestation surges during COVID-19 pandemic

Author:
Bruce Jancin
Publish date: February 4, 2021

Experts weigh in on management of this challenging disorder marked by tenacious false beliefs.

  • Read More

News

Adalimumab enhances primary wound closure after HS surgery

Author:
Bruce Jancin
Publish date: February 2, 2021

Primary wound closure following surgery for HS is controversial.

  • Read More

News

Hypochlorous acid is a valuable adjunctive treatment in AD

Author:
Bruce Jancin
Publish date: February 2, 2021

Stabilized topical hypochlorous acid has potent antimicrobial and antipruritic effects.

  • Read More

News

Topical brepocitinib for atopic dermatitis meets endpoints in phase 2b study

Author:
Bruce Jancin
Publish date: January 29, 2021

First-in-class inhibitor of tyrosine kinase 2 and Janus kinase 1 scores for mild-to-moderate AD.

  • Read More

News

Expert highlights advances in DRESS

Author:
Bruce Jancin
Publish date: January 28, 2021

Recent data demonstrate that DRESS symptoms often occur within just a week or two of drug exposures.

  • Read More

News

Oral JAK1 inhibitor shows promise for hidradenitis suppurativa

Author:
Bruce Jancin
Publish date: January 26, 2021

Favorable safety and efficacy shown in phase 2, proof-of-concept studies.

  • Read More

News

Guselkumab maintains psoriasis efficacy long after discontinuation

Author:
Bruce Jancin
Publish date: January 26, 2021

A potential flexible dosing indication for the IL-23 inhibitor is under study.

  • Read More

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »

Privacy Policy

Do Not Sell My Personal Information

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close